# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Brookline Capital analyst Kumaraguru Raja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and anno...
The SAB Board of Directors has launched a formal search process to identify King's permanent replacement. Mark Conley, SAB&...
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $25 price target.
HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $6 price ...
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $...
HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $6 price ...
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and maintains $25 price target.